Cervical cytology readers reduce false negatives
This article was originally published in Clinica
The false negative rate for Pap tests should be reduced with the cervical cytology readers reviewed by the US FDA advisory panel this month. Unanimously recommending approval for Neuromedical Systems' Papnet and Neopath's AutoPap analysers on August 7th and 8th (see Clinica No 667, p 1), the Haematology and Pathology Devices Advisory Panel noted that cervical cancer responds favourably to treatment if detected early by Pap test. However false negative rates for Pap tests are on average 25%.